GPR183 and breast cancer: In vivo validation using immunohistochemistry on clinical samples from 10 breast cancer patients with ovarian metastases confirmed that GPR183, BHLHE41, and CD83 were highly expressed in tumor tissues, while SLC25A37 and SELL were highly expressed in adjacent normal tissues.